Recent Updates in The Role of Immunotherapies in Early NSCLC: Translating Evidence to Clinical Practice - Episode 5

Perioperative Treatment in Early NSCLC: KEYNOTE-671 and NEOTORCH Studies

July 6, 2023

Tina Cascone, MD, PhD, Sandip Patel, MD, Benjamin Levy, MD, David H. Harpole Jr, MD

Sandip Patel, MD, reviews the study design, results and clinical implications of the KEYNOTE-671 and NEOTORCH studies that evaluated perioperative chemoimmunotherapy in the treatment of early-stage NSCLC.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Overview of Early-Stage NSCLC and Molecular Testing

EP. 2: Selecting Optimal Treatment in Early-Stage NSCLC

EP. 3: Neoadjuvant Therapy in Early-Stage NSCLC: CheckMate-816 Study

EP. 4: Perioperative Treatment in Early-Stage NSCLC: AEGEAN Study

Now Viewing

EP. 5: Perioperative Treatment in Early NSCLC: KEYNOTE-671 and NEOTORCH Studies

EP. 6: Neoadjuvant Versus Perioperative Therapy in Resectable NSCLC

EP. 7: Neoadjuvant Versus Adjuvant Therapy in Resectable NSCLC

EP. 8: Adjuvant Therapy in NSCLC: IMPower-010 and KEYNOTE-091 Studies

EP. 9: Treatment Strategy in Patients with Unresectable Stage I-III NSCLC

EP. 10: Consolidation Immunotherapy in Unresectable Early NSCLC: PACIFIC Study

EP. 11: Consolidation Immunotherapy in Unresectable Early NSCLC: Novel Approaches

EP. 12: Treatment for Patients Unsuitable for or Refractory to Consolidation Durvalumab

EP. 13: Practice Pearls for Community Oncologists Treating Early-Stage NSCLC